A Phase 2, Single-Arm, Open-label, Study of RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2017
At a glance
- Drugs RRx 001 (Primary) ; Cisplatin; Gemcitabine
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors EpicentRx
- 02 Jul 2017 Planned End Date changed from 1 May 2018 to 1 Aug 2017.
- 02 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017.
- 29 Oct 2016 Status changed from recruiting to active, no longer recruiting.